The Hepatitis C Therapeutic Registry and Research Network, or HCV-TARGET, is an international research consortium created to inform the ongoing transformation of hepatitis C treatment and research. Led jointly by the University of Florida and the University of North Carolina at Chapel Hill, HCV-TARGET includes 103 academic and community sites in 31 states, Puerto Rico, Canada and Europe as well as partnerships with multiple industry sponsors, regulatory agencies and the patient advocacy community. As more patients get tested for hepatitis C and as new treatments enter the market, HCV-TARGET aims to objectively reflect, inform and improve the hepatitis C patient experience across diverse populations. HCV-TARGET is conducting an investigator-initiated observational study jointly sponsored by UF and UNC and funded in part by Vertex; Merck; Kadmon; and Genentech through PEGBASE: An Observational Study.